C2I is home to over 25 biotechnology startups with the capability to provide more than 50 life science entrepreneurs a place to call home. Our residents have created over 100 highly skilled jobs and C2I had helped make an economic impact of 450M+ in funds raised in the Commonwealth.
Archimmune is an immuno-oncology platform company. Its first program is aimed at developing standardized antigen capturing nanoparticles that form a personalized, systemically-acting cancer vaccine in situ when injected intra-tumorally following radiotherapy. The second program exploits the ability of nanocarriers to simultaneously and bi-/tri-specifically engage with selected tumor and/or IO targets.
Fieldstone is a new biotechnology company bringing innovative remote-sensing technology to agriculture.
Analog Devices is a global semiconductor leader that bridges the physical and digital worlds to enable breakthroughs at the Intelligent Edge. They combine analog, digital, and software technologies into solutions that help drive advancements in digitized factories, mobility, and digital healthcare, combat climate change, and reliably connect humans and the world.
100X Bioassay strives to deliver 100-1000x more data on antigen specificity of the T cells in the limited sample volume (blood, LN, tumor, etc.), and as the downstream -- matching of the precise antigen specificity with TCR sequence.
PAQ’s global team is pioneering a new approach to restoring health and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation.
Prolacta Bioscience discovers, develops, and delivers life-changing solutions for critically ill babies and other vulnerable patients. They achieve this through innovative human milk research and leadership in quality and safety.
AlpaLifeB Inc. focuses on both the U.S. and global markets to distribute nanobody reagents to research labs in academia and industry. They also provide customers with nanobody discovery services for the guarantee of generating high affinity and specific unique therapeutic nanobodies/VHH candidates from alpaca and llama against targets of interests.
Cellens is pioneering in label-free cell analysis with a combination of high-resolution nanoscale imaging and proprietary machine learning.
Anagenex is building a directed evolution platform to develop new small molecules by combining massively parallel biochemical experiments and machine learning.
This is all I have for them: Anastasis Bio is a research-stage company founded in 2020 to develop therapeutics inspired by the work of professors Denise Montell of UC Santa Barbara and Shoukat Dedhar of The University of British Columbia. Our research focuses on targeting novel pathways involved in tumor cell survival, proliferation, and metastasis.
Revela is helping women struggling with hair thinning with their products using ProCelinyl™, the first and only ingredient that directly supports your hair follicles. Existing solutions support increased blood flow, DHT inhibition, and overall nutrition and wellness in hopes that your body will produce healthier hair. ProCelinyl focuses its attention directly on your follicles to effectively reawaken your roots.
MarvelBiome, Inc. is a biopharmaceutical company with a vision of harnessing the power of microbes for treating various human diseases.
Mellitus is dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. Their premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mother and child.
Fosun Pharma, a leading healthcare group in China, strives to be one of the first-class enterprises in the global mainstream healthcare market.
Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. Alto, the world’s first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines.
DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. Their vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.
A biotechnology company intended to develop human antibodies as therapeutics for infectious disease.
CreaGen Inc. is a premier chemistry-based drug discovery service company that provides cost-effective, high quality discovery research services to biotech and pharmaceutical companies.
Frequency Therapeutics is a platform technology with an initial focus on chronic hearing loss, a potential $10B+ US market with no effective therapeutic solution. Other potential applications include gastrointestinal diseases and diabetes.
SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics.
Nano-C started operations in 2001, and is a leader in the world of nano-structured carbon materials and chemicals.
SQZ Biotech is a company founded out of the Massachusetts Institute of Technology (MIT). At SQZ, they have developed a high-throughput platform - CellSqueeze - for simple and effective material delivery into cells.
Ankaa Therapeutics is a leader in developing targeted small molecule drugs for personalized therapy.
Snapdragon Chemistry is headquartered in Boston, MA and is a leading provider of flow chemistry solutions and services.
Rilas Technologies provides services in the areas of purification of small molecule drug candidates from early discovery through to clinical phases.
Mercury Therapeutics Inc is a biotechnology company based out of 2 Gill St, Woburn, Massachusetts, United States.
MaxThera's strategy is to limit resistance emergence to combine the use of these new targets in biosynthetic pathways - essential for bacterial survival - with novel structural classes of compounds.